- Home
- CLPT vs CTNM Comparison
CLPT vs CTNM Comparison
Compare CLPT & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLPT | CTNM |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.6M | 416.1M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | CLPT | CTNM |
|---|---|---|
| Price | $14.69 | $11.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $27.67 | $18.60 |
| AVG Volume (30 Days) | ★ 635.3K | 255.0K |
| Earning Date | 02-25-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,332,000.00 | N/A |
| Revenue This Year | $18.93 | N/A |
| Revenue Next Year | $51.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $9.76 | $3.35 |
| 52 Week High | $30.10 | $13.49 |
Technical Indicators
Market Signals| Indicator | CLPT | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 58.06 |
| Support Level | $13.80 | $8.92 |
| Resistance Level | $16.58 | $11.90 |
| Average True Range (ATR) | 1.01 | 0.92 |
| MACD | 0.11 | 0.15 |
| Stochastic Oscillator | 37.34 | 79.84 |
Price Performance
Historical ComparisonAbout CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.